Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government... (s is an important new position for our C...)

Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances

Date:7/21/2009

s is an important new position for our Company and is reflective of the continued evolution of Novavax in the vaccine space. John brings a unique blend of skills in vaccine product positioning strategy, government relations, and commercial markets to augment our existing management team to capitalize on the new opportunities available to the Company."

Mr. Trizzino is a graduate of Long Island University and received his master's degree in business administration from New York University's Stern School of Business.

About Novavax

Novavax, Inc. is a clinical stage biotechnology company, creating novel vaccines to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new, and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related biology technology :

1. Novavax Announces Repayment of $5 Million of Convertible Debt
2. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
3. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
4. Novavax Appoints Stanley Erck to Board of Directors
5. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
6. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
7. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
8. Novavax Reports First Quarter 2009 Financial Results
9. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
10. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
11. Novavax Announces Early Retirement of $17 Million of Convertible Debt

Post Your Comments:

(Date:6/19/2013)... Adding to their already extensive supply of ... Dropette® and Heathrow Scientific disposable plastic transfer ... biology, chemistry and any type of liquid handling analysis ... years, Simport has been supplying the science community with ... Simport Dropette®. Simport’s Dropette® is a one-piece plastic ...

(Date:6/18/2013)... China Cord Blood Corporation (NYSE: CO ) ... blood collection, laboratory testing, hematopoietic stem cell processing, and ... financial results for the fourth quarter and full year ... Fourth Quarter of Fiscal 2013 Highlights ... increased by 33.3% to RMB133.0 million ($21.4 million) from ...

(Date:6/18/2013)... The Regulatory Affairs Professionals Society ... in Asia—one in Singapore and one in Shanghai, China. ... Pan-Asia office , serving the Asia Pacific region, and ... within China. , The announcement comes just a few ... government agencies to develop and implement a new ...

(Date:6/18/2013)... (PRWEB) June 18, 2013 DuPont welcomes ... the 11th annual DuPont National AgriScience Teachers Ambassador Academy ... in Chestertown, Md. , The NATAA ... DuPont and is a special project of the ... of Agricultural Educators (NAAE) . The highly recommended ...

[0] Leading Pipette Distributor Pipette.com Now Stocks Transfer Pipettes: Simport’s Dropette and Heathrow Scientific Disposable Plastic Transfer Pipettes [0] China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 [0] RAPS Opens Offices in Singapore and China [0] DuPont Sponsors National AgriScience Ambassador Academy

... VANCOUVER, April 17 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. ... global specialty pharmaceutical and,medical device company, today ... the U.S. Food and Drug Administration (FDA) ... Catheter (CVC) in,the United States., "The ...

... with Increased Investment in ... Research & Development, DEERFIELD, Ill., April 17 ... for,the first quarter of 2008, and raised its financial outlook for the ... million, a 6,percent increase compared to $403 million in the first quarter ...

... and more transparency in federal risk research investment, the ... rather than a foregone conclusion, says Dr. Andrew Maynard, ... Nanotechnologies (PEN). This sentiment was voiced today by Dr. ... Committees hearing on the National Nanotechnology Initiative Amendments Act ...

Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance Baxter Reports Solid First Quarter Financial Results and Raises Full-Year Outlook Limited transparency in federal nanotech research may hamper development

(Date:6/18/2013)... Scientists at the University of Calgary,s Faculty of Medicine ... the body from harmful bacteria. Platelets, a component of ... search for specific bacteria, and upon detection, seal it ... which were published in Nature Immunology this ... of immunity. , "The science community has known that ...

(Date:6/18/2013)... University, sophisticated computational models and advances in graphical ... interplay between genomic data, virus structure and the ... for replication. , "We hope that ... researchers alter virus assembly, leaving viruses unable to ... of the scientific paper describing the technique, published ...

(Date:6/18/2013)... National Institutes of Health has awarded $12.7 million ... selection of pharmaceutical industry compounds to explore new ... Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. The ... for Existing Molecules, is led by the National ... by the NIH Common Fund. , The process ...

Breaking Biology News(10 mins):Immunity mechanism discovered 2 Computer modeling technique goes viral at Brandeis 2 NIH to fund collaborations with industry to identify new uses for existing compounds 2 NIH to fund collaborations with industry to identify new uses for existing compounds 3 NIH to fund collaborations with industry to identify new uses for existing compounds 4

[0] Immunity mechanism discovered [0] Computer modeling technique goes viral at Brandeis [0] NIH to fund collaborations with industry to identify new uses for existing compounds

... experimental drug prevented and treated both type 2 diabetes ... unhealthy diets and were genetically predisposed to these common ... on June 6, 2007. The team was led by ... Genetics and Complex Diseases at the Harvard School of ...

... very cold case: the disappearance of the last woolly mammoths, ... according to a June 7th report published online in Current ... the bones, teeth, and tusks of the extinct mammoths revealed ... interglacial period. After the mammoths’ migration, the population apparently leveled ...

... University of Minnesota researchers report that umbilical cord ... outcomes than bone marrow transplants, according to an ... for International Blood and Marrow Transplant Research (CIBMTR), ... the first study that directly compares matched bone ...

Cached Biology News:In mice, drug protects against diabetes and atherosclerosis 2 In mice, drug protects against diabetes and atherosclerosis 3 In mice, drug protects against diabetes and atherosclerosis 4 Ancient DNA traces the woolly mammoth's disappearance 2 Research shows cord blood comparable to matched bone marrow 2 Research shows cord blood comparable to matched bone marrow 3

In mice, drug protects against diabetes and atherosclerosis Ancient DNA traces the woolly mammoth's disappearance Research shows cord blood comparable to matched bone marrow

Request Info...

Tracker Datamatrix RS-1* reads 96 2D Bar-coded tubes within 20 seconds....

Hybridization cassette for one slide...

Complete cell culture media with cytokines...

Biology Products:

RayBio Human Cytokine Antibody Array I &1.1 Service from Raybiotech, Inc.Tracker Datamatrix RS-1* from Micronic BV TAKARA HYBRIDIZATION CHAMBER 1 from Takara Mirus Bio Stem Cell Expansion Media 1 from 3H Biomedical AB